Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference

Rhea-AI Summary

Dyne Therapeutics, focused on innovative therapies for muscle diseases, announced its participation in Chardan’s Virtual 5th Annual Genetic Medicines Conference. Management, including CEO Joshua Brumm and CSO Oxana Beskrovnaya, will engage in a fireside chat on October 5, 2021, at 9:00 a.m. ET. The event will feature a live webcast available on Dyne's website, with replay access for 90 days. Dr. Beskrovnaya will also speak in a panel on RNA-based delivery approaches. The company is advancing therapeutics for conditions like Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

WALTHAM, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during Chardan’s Virtual 5^th Annual Genetic Medicines Conference.

Joshua Brumm, Dyne’s president and chief executive officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, will participate in a fireside chat on October 5, 2021 at 9:00 a.m. ET. A live webcast of the chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

Dr. Beskrovnaya is also an invited speaker on a panel, “RNA-based Targeted Delivery Approaches,” which will be available to conference participants.  

About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne’s broad portfolio of therapeutic candidates for serious muscle diseases includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com  
857-341-1203

 

FAQ

What is the date and time of Dyne Therapeutics' presentation at the conference?

Dyne Therapeutics will present at Chardan’s Virtual 5th Annual Genetic Medicines Conference on October 5, 2021, at 9:00 a.m. ET.

Who will represent Dyne Therapeutics at the conference?

Joshua Brumm, CEO, and Oxana Beskrovnaya, CSO, will represent Dyne Therapeutics at the conference.

Where can I watch the live webcast of Dyne's presentation?

The live webcast of Dyne's presentation will be available in the Investors & Media section of Dyne’s website.

How long will the replay of Dyne's conference presentation be accessible?

The replay of Dyne's conference presentation will be accessible for 90 days following the event.

What topics will Dr. Oxana Beskrovnaya discuss at the conference?

Dr. Oxana Beskrovnaya will participate in a panel discussing RNA-based targeted delivery approaches.

What diseases is Dyne Therapeutics focusing on with its therapeutics?

Dyne Therapeutics is developing therapies for serious muscle diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).